--- title: "Keros Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 367 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286412781.md" datetime: "2026-05-14T12:03:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286412781.md) - [en](https://longbridge.com/en/news/286412781.md) - [zh-HK](https://longbridge.com/zh-HK/news/286412781.md) --- # Keros Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 367 K Revenue: As of FY2026 Q1, the actual value is USD 367 K, missing the estimate of USD 1.688 M. EPS: As of FY2026 Q1, the actual value is USD -1.21, missing the estimate of USD -1.0229. EBIT: As of FY2026 Q1, the actual value is USD -25.88 M. #### Net Income (Loss) Keros Therapeutics, Inc. reported a net loss of - $23.7 million in the first quarter of 2026, a significant decrease of $172.2 million compared to a net income of $148.5 million in the first quarter of 2025. This decline was primarily attributed to revenue recognized in 2025 from a license agreement with Takeda and reduced research and development efforts . #### Total Revenue Total revenue for the first quarter of 2026 was $367 thousand, a substantial decrease from $211,246 thousand in the same period of 2025 . **Service and Other Revenue**: $367 thousand in Q1 2026, compared to $15,891 thousand in Q1 2025 . **License Revenue**: No license revenue was reported in Q1 2026, compared to $195,355 thousand in Q1 2025 . #### Operating Expenses - **Research and Development Expenses**: $16.1 million for the first quarter of 2026, a decrease of $32.6 million from $48.7 million in the first quarter of 2025. This reduction was mainly due to the transition of elritercept-related research and development expenses to Takeda and a corporate restructuring in 2025 . - **General and Administrative Expenses**: Decreased by $0.4 million to $10.1 million in Q1 2026 from $10.5 million in Q1 2025, primarily due to lower compensation costs related to the 2025 corporate restructuring . - **Total Operating Expenses**: $26,244 thousand for Q1 2026, compared to $59,206 thousand for Q1 2025 . #### Income (Loss) from Operations Income (loss) from operations was - $25,877 thousand for the first quarter of 2026, a significant change from an income of $152,040 thousand in the first quarter of 2025 . #### Other Income (Expense), Net Total other income, net was $2,169 thousand for the first quarter of 2026, down from $6,454 thousand in the same period of 2025 . #### Cash and Cash Equivalents Keros Therapeutics, Inc.’s cash and cash equivalents stood at $281.5 million as of March 31, 2026, a slight decrease from $287.4 million as of December 31, 2025 . #### Balance Sheet Highlights (in thousands) - **Accounts Receivable**: $400 as of March 31, 2026, compared to $3,567 as of December 31, 2025 . - **Prepaid Expenses and Other Current Assets**: $6,530 as of March 31, 2026, compared to $22,202 as of December 31, 2025 . - **Total Current Assets**: $290,677 as of March 31, 2026, compared to $315,434 as of December 31, 2025 . - **Total Assets**: $312,293 as of March 31, 2026, compared to $338,021 as of December 31, 2025 . - **Accounts Payable**: $1,493 as of March 31, 2026, compared to $1,967 as of December 31, 2025 . - **Accrued Expenses and Other Current Liabilities**: $8,859 as of March 31, 2026, compared to $16,039 as of December 31, 2025 . - **Total Current Liabilities**: $12,853 as of March 31, 2026, compared to $20,414 as of December 31, 2025 . - **Total Liabilities**: $26,663 as of March 31, 2026, compared to $34,889 as of December 31, 2025 . - **Total Stockholders’ Equity**: $285,630 as of March 31, 2026, compared to $303,132 as of December 31, 2025 . #### Outlook / Guidance Keros Therapeutics, Inc. anticipates that its cash and cash equivalents of $281.5 million as of March 31, 2026, will be sufficient to cover its operating expenses and capital expenditure requirements into the first half of 2028 . Additionally, the company’s partner, Takeda Pharmaceuticals U.S.A., Inc., intends to progress elritercept into a Phase 3 clinical trial for the treatment of anemia in myelofibrosis, thereby expanding its potential indications . ### Related Stocks - [KROS.US](https://longbridge.com/en/quote/KROS.US.md) ## Related News & Research - [Keros Therapeutics to receive $20 million Takeda milestone payment for elritercept Phase 3 dosing](https://longbridge.com/en/news/294408894.md) - [Keros Therapeutics names Annita Tanini interim CFO as Keith Regnante resigns](https://longbridge.com/en/news/293513881.md) - [SRX Global amends 8-K to correct CFO Carolina Martinez misidentified as CEO](https://longbridge.com/en/news/294232884.md) - [Standard BioTools amends 8-K to file mass cytometry sale agreement with Multiplex Bio](https://longbridge.com/en/news/294206092.md) - [American Resources files amended 8-K detailing auditor change timeline after GreenGrowth withdraws 2025 opinion](https://longbridge.com/en/news/294229412.md)